Publications by authors named "Scott Wardwell"

Claim this Profile
D
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Wei-Sheng Huang, Feng Li, Yongjin Gong, Yun Zhang, Willmen Youngsaye, Scott D Wardwell

Bioorg Med Chem Lett· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobocertinib (TAK-788): A Targeted Inhibitor of Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Francois Gonzalvez, Sylvie Vincent, Theresa E Baker, Alexandra E Gould, Shuai Li, Scott D Wardwell

Cancer Discov· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
Joseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott Wardwell, Frank Wang

Oncotarget· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Scott D Wardwell

Clin Cancer Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Wei-Sheng Huang, Shuangying Liu, Dong Zou, Mathew Thomas, Yihan Wang, Scott D Wardwell

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Scott Wardwell

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Joseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, David Miller, Scott Wardwell

Cancer Chemother Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Rachel M Squillace, David Miller, Scott D Wardwell, Frank Wang, Tim Clackson

Int J Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Joseph M Gozgit, Matthew J Wong, Lauren Moran, Scott Wardwell, Qurish K Mohemmad

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D Wardwell

Chem Biol Drug Des· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
Rachel M Squillace, David Miller, Michelle Cookson, Scott D Wardwell, Lauren Moran

Mol Cancer Ther· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Joseph M Gozgit, Matthew J Wong, Scott Wardwell, Jeffrey W Tyner, Marc M Loriaux

Mol Cancer Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Victor M Rivera, Rachel M Squillace, David Miller, Lori Berk, Scott D Wardwell

Mol Cancer Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Mathew Thomas, Wei-Sheng Huang, David Wen, Xiaotian Zhu, Yihan Wang, Scott Wardwell

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, Yihan Wang, Dong Zou, Scott Wardwell

J Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, Christopher A Eide, Victor M Rivera, Scott Wardwell

Cancer Cell· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Wei-Sheng Huang, Xiaotian Zhu, Yihan Wang, Mohammad Azam, David Wen, Scott Wardwell

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Yihan Wang, William C Shakespeare, Wei-Sheng Huang, Raji Sundaramoorthi, Scott Lentini, Scott Wardwell

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
William C Shakespeare, Yihan Wang, Regine Bohacek, Terry Keenan, Raji Sundaramoorthi, Scott Wardwell

Chem Biol Drug Des· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Amie S Corbin, Shadmehr Demehri, Ian J Griswold, Yihan Wang, Chester A Metcalf, Scott Wardwell

Blood· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologically regulated in vivo selection in a large animal.
Tobias Neff, Peter A Horn, Victor E Valli, Allen M Gown, Scott Wardwell

Blood· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis